Drug Profile
AGN 195263
Alternative Names: AGN-195263Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Developer AbbVie
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry eyes
- Phase II Meibomianitis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 28 Jun 2017 Allergan terminates a phase III trial for Dry eyes in USA (Ophthalmic) (NCT02815293)
- 01 Dec 2016 Allergan initiates enrolment in a phase III trial for Dry eyes in USA (NCT02965846)